At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to ...

The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.

The FDA has approved ProlivRx, the first prescription, home-based brain neuromodulation therapy, as an adjunctive treatment ...

ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...

The FDA approved a prescription at-home brain neuromodulation therapy as an adjunctive depression treatment for adults, maker ...

The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that ...

Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...

PLANO, Texas, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, ...

Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...

ReShape Lifesciences® announced the presentation of pre-clinical data for its innovative Diabetes Neuromodulation device at the Minnesota Neuromodulation Symposium. This device employs Hypoglycemia ...